MyFinsight
Home
Blog
About
Vivitrol
$124,454,000
Aristada And Aristada
Initio
$96,719,000
LUMRYZ
$96,572,000
LYBALVI
$93,979,000
Royalty
$63,384,000
Manufacturing Revenue
$20,901,000
Product
$411,724,000
(34.01%↑ Y/Y)
Manufactured Product And
Royalty
$84,285,000
(1.03%↑ Y/Y)
Income tax provision
(benefit)
-$2,377,000
(-113.40%↓ Y/Y)
Total revenues
$496,009,000
(26.97%↑ Y/Y)
Net (loss) income
$501,000
(-99.42%↓ Y/Y)
Foreign currency
translation gain
$240,000
(loss) income before
income taxes
-$1,876,000
(-101.79%↓ Y/Y)
Operating (loss) income
$18,353,000
(-80.26%↓ Y/Y)
Total expenses
$477,656,000
(60.46%↑ Y/Y)
Comprehensive (loss) income
$486,000
(-99.44%↓ Y/Y)
Holding (loss) gain, net
of a tax (benefit)...
-$255,000
(-563.64%↓ Y/Y)
Total other (expense)
income, net
-$20,229,000
(-270.55%↓ Y/Y)
Interest income
$5,344,000
(-51.81%↓ Y/Y)
Other (expense)
income, net
$352,000
Selling, general and
administrative
$217,625,000
(27.38%↑ Y/Y)
Research and development
$112,920,000
(45.95%↑ Y/Y)
Cost of goods
manufactured and sold...
$98,112,000
(98.37%↑ Y/Y)
Change in fair value of
contingent consideration
$26,414,000
Amortization of acquired
intangible assets
$22,585,000
Interest expense
$25,925,000
Back
Back
Income Statement
Alkermes plc. (ALKS)
Alkermes plc. (ALKS)
source: myfinsight.com